Local secretion of IFN-γ induces an antitumor response: Comparison between T cells plus IL-2 and IFN-γ transfected tumor cells

Journal of Immunotherapy

Volumn 22, Issue 4, 1999, Pages 315-323

  Sadanaga, Noriaki ^a   Nagoshi, Makoto ^a   Lederer, James A ^a   Joo, Hong Gu ^a   Eberlein, Timothy J ^a   Goedegebuure, Peter S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dendritic cells; IFN ; Immunotherapy; Macrophages; MCA 105

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; NITRIC OXIDE SYNTHASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FIBROSARCOMA; GENE TRANSFER; GENETIC TRANSFECTION; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

EID: 0033023734     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199907000-00005     Document Type: Article

References (34)

1. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635-44.
2. Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard VF, Eberlein TJ. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res 1990;50:2587-92.
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
4. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991;147:729-37.
5. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. Gammainterferon plays a key role in T-cell-induced tumor regression. Cancer Res 1993;53:833-9.
6. Burger UL, Chang MP, Goedegebuure PS, Eberlein TJ. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. Surgery 1995;117:325-33.
7. Goedegebuure PS, Zuber M, Leonard VD, et al. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 1994;3:79-89.
8. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokines (IFN-γ and GM-CSF) producing donor tumorinfiltrating lymphocytes. J Immunol 1998;160:334-44.
9. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
10. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995;13:1939-49.
11. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993;259:1739-42.
12. Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcomas. J Natl Cancer Inst 1977;58:1303-9.
13. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
14. Matory YL, Chen M, Dorfman DM, Williams A, Goedegebuure PS, Eberlein TJ. Antitumor activity of three mouse mammary cancer cell lines after interferon-gamma gene transfection. Surgery 1995;118:251-6.
15. Area MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996;42:237-45.
16. Kelly JL, Lyons A, Soberg CC, Mannick JA, Lederer JA. Antiinterleukin-10 antibody restores bum-induced defects in T-cell function. Surgery 1997;122:146-52.
17. Fekete E. A comparative morphological study of the mammary gland in a high and low tumor strain of mice. Am J Pathol 1938;14:557-78.
18. Nagoshi M, Goedegebuure PS, Eberlein TJ. Successful adoptive cellular immunotherapy is associated with enhanced production of IFN-gamma at tumor sites induced by donor T cells. Surg Forum 1996;47:465-7.
19. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-64.
20. Barth RJJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
21. Aruga A, Shu S, Chang AE. Tumor-specific granulocyte/ macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 1995;41:317-24.
22. Wallach D, Fellous M, Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982;299:833-6.
23. Collins T, Korman AJ, Wake CT, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984;81:4917-21.
24. + lymphocyte clones reactive with melanoma: the role of HLA and accessory molecules. Vaccine Res 1993;2:249-61.
25. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-4.
26. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol 1993;150:1458-70.
27. Yu WG, Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996;8:855-65.
28. Doherty GM, Tsung K, McCluskey B, Norton JA. Endogenous interferon-gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res 1996;64:68-74.
29. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 1997;18:32-6.
30. Pardoll D. New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4:619-23.
31. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
32. Lu L, Bonham CA, Chambers FG, et al. Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996;157:3577-86.
33. Stenger S, Donhauser N, Thuring H, Rollinghoff M, Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 1996;183:1501-14.
34. Xie K, Huang S, Dong Z, Juang SH, Wang Y, Fidler IJ. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997;89:421-7.